- Home
- NWL vs GHRS Comparison
NWL vs GHRS Comparison
Compare NWL & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NWL | GHRS |
|---|---|---|
| Founded | 1903 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NWL | GHRS |
|---|---|---|
| Price | $6.17 | $29.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $4.97 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 10.4M | 378.2K |
| Earning Date | 05-01-2026 | 05-01-2026 |
| Dividend Yield | ★ 7.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $14,742,200,000.00 | N/A |
| Revenue This Year | $1.19 | N/A |
| Revenue Next Year | $1.58 | N/A |
| P/E Ratio | $36.24 | ★ N/A |
| Revenue Growth | ★ 11.14 | N/A |
| 52 Week Low | $3.07 | $11.83 |
| 52 Week High | $7.13 | $31.44 |
Technical Indicators
Market Signals| Indicator | NWL | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 62.69 | 62.78 |
| Support Level | $3.32 | $25.66 |
| Resistance Level | $6.20 | $31.00 |
| Average True Range (ATR) | 0.40 | 1.43 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 54.68 | 76.57 |
Price Performance
Historical ComparisonAbout NWL Newell Brands Inc.
Newell Brands Inc is an American consumer goods company with a portfolio of brands, including Rubbermaid, Sharpie, Graco, Coleman, Rubbermaid Commercial Products, Yankee Candle, Paper Mate, FoodSaver, Dymo, EXPO, Elmer's, Oster, NUK, Spontex and Campingaz. The group is focused on delighting consumers by lighting up everyday moments. Its segments are Home and Commercial Solutions, Learning and Development, and Outdoor and Recreation. The group geographic areas are the United States, Canada, Europe, the Middle East and Africa, Asia Pacific, and Latin America.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.